» Articles » PMID: 2872872

Islets of Langerhans in Adolescents and Adults with Cystic Fibrosis. A Quantitative Study

Overview
Specialty Pathology
Date 1986 Jul 1
PMID 2872872
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence of fasting hyperglycemia and diabetes mellitus (DM) in older patients with cystic fibrosis (CF) is reported to be 8%, but few quantitative studies of the islets of Langerhans in this disease have been done. Three groups of patients were studied in this morphometric autopsy analysis: patients with CF and insulin-dependent DM (n = 7), normoglycemic patients with CF (n = 4), and age-matched adolescents and young-adult controls (n = 11). The islets of Langerhans were stained with immunoperoxidase for insulin, glucagon, and somatostatin. The percentage of the total islet surface area occupied by each immunoperoxidase positive cell type was determined by a point-counting method. The mean percent surface area occupied by insulin-producing cells (28.3%) in diabetics with CF was significantly less than normoglycemics with CF (46.7%) and controls (53.4%). The mean percent surface area occupied by glucagon-producing cells was similar in all three groups: 21.9% in CF diabetics, 25.4% in normoglycemics with CF, and 22.4% in controls. The mean percent surface area occupied by somatostatin was increased in both CF groups compared with controls: diabetics with CF, 29.3%; normoglycemics with CF, 26.2%; and controls, 15.5%. These findings correlate with published clinical endocrine studies of hyperglycemia in CF. Endocrine cell quantitation in diabetics with CF differs from that in both juvenile (type 1) and adult-onset (type 2) DM.

Citing Articles

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.


Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes.

Malik S, Padmanabhan D, Hull-Meichle R Front Endocrinol (Lausanne). 2023; 14:1269139.

PMID: 38075070 PMC: 10704027. DOI: 10.3389/fendo.2023.1269139.


Increased sputum lactate during oral glucose tolerance test in cystic fibrosis.

Jensen P, Nielsen B, Kolpen M, Pressler T, Faurholt-Jepsen D, Mathiesen I APMIS. 2022; 130(8):535-539.

PMID: 35635299 PMC: 9545947. DOI: 10.1111/apm.13233.


The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes.

Hasan S, Soltman S, Wood C, Blackman S J Clin Transl Endocrinol. 2022; 27:100287.

PMID: 34976741 PMC: 8688704. DOI: 10.1016/j.jcte.2021.100287.


Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes.

Al-Selwi Y, Shaw J, Kattner N Clin Med Insights Endocrinol Diabetes. 2021; 14:11795514211048813.

PMID: 34675737 PMC: 8524685. DOI: 10.1177/11795514211048813.